Who is sponsoring NCT03579589?

NCT03579589 is sponsored by Ohio State University.

What drugs are being tested in NCT03579589?

Interventions in NCT03579589: Sugammadex vs Neostigmine.

What condition does NCT03579589 study?

NCT03579589 studies Neuromuscular Blockade.

Is NCT03579589 still recruiting?

NCT03579589 is currently completed. Last updated 11 August 2021.

Last reviewed 2021-08-11 · How we verify

NCT03579589

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of Sugammadex Versus Neostigmine During Neuromuscular Blockade Reversal

Completed Phase 1 Last updated 11 August 2021

What this trial tests

Phase 1 trial testing Sugammadex vs Neostigmine in Neuromuscular Blockade in 40 participants. Completed in 15 December 2019.

Timeline

15 August 2018

Primary endpoint
15 December 2019

15 December 2019

Quick facts

Lead sponsor	Ohio State University
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	15 August 2018
Primary completion	15 December 2019
Estimated completion	15 December 2019
Sites	1 location across United States

Drugs / interventions tested

Sugammadex vs Neostigmine

Conditions studied

Neuromuscular Blockade — all drugs for Neuromuscular Blockade →

Sponsor

Ohio State University

Who can join

18 and older, any sex, with Neuromuscular Blockade. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients who undergo surgery receive drugs called neuromuscular blocking agents (NMBA) that to block the activity of muscles. When the surgery is over, the block needs to be reversed. Suggammadex and neostigmine are examples of drugs that reverse blocks. This study aims to investigate if sugammadex is associated with a significantly reduced time to discharge from the operating room to the postoperative unit when compared to neostigmine.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Sugammadex versus neostigmine for neuromuscular blockade reversal in outpatient surgeries: A randomized controlled trial to evaluate efficacy and associated healthcare cost in an academic center.
Fiorda Diaz J, Echeverria-Villalobos M, Esparza Gutierrez A, Dada O, et al · · 2022 · cited 8× · PMID 36569123 · DOI 10.3389/fmed.2022.1072711

Verify or expand the search:

Other recruiting trials for Neuromuscular Blockade

Currently open trials in the same condition.

NCT07203287 — Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease · Phase 4 · recruiting
NCT06945341 — International Focus Group Discussion on Neuromuscular Monitoring. · recruiting
NCT06948409 — NMBA Reversal and Postoperative Urinary Retention · active not recruiting
NCT07003061 — Sarcopenia and Neuromuscular Block in Gastrointestinal Cancer Surgery · recruiting
NCT06679569 — Deep Neuromuscular Blockade on Postoperative Pain · NA · recruiting

Other Ohio State University trials

Trials by the same sponsor.

NCT06542458 — Under-Represented Communities Diagnosed With SCD or MCI Through Tele-Cog · not yet recruiting
NCT07217548 — Solving Stigma Through POV Simulation: Enhancing Pharmacist Empathy-based Practices With Sickle Cell Disease Patients · NA · enrolling by invitation
NCT07215221 — Implementation of TBI-RECOVER in Substance Use Treatment · NA · not yet recruiting
NCT07278427 — Reducing Parental Substance Use and Enhancing Family Resilience Among Rural Families Through Ohio START · recruiting
NCT07490444 — Metric-Optimized Spectacle Prescriptions for Children With Down Syndrome · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03579589 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ohio State University
Last refreshed: 11 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03579589.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing